Willow Biosciences – one of a clutch of biotech firms producing cannabinoids via biosynthesis rather than extraction – has started strain optimization and process development for commercial production of astaxanthin from yeast using a downstream processing...
A new player is on the verge of entering the astaxanthin and other markets with the granting of a patent on a ‘dark fermentation’ process for cultivating Haematococcus pluvialis and other algae species.
Israeli company NextFerm Technologies Inc. has raised $9.2 million in an initial public offering on the Tel Aviv stock exchange, the company announced today.
A recent review of astaxanthin found evidence to support the safety of dosages of 12 mg up to 24 mg a day. But that applies to only to natural astaxanthin, not to the synthetic forms, the authors said.